Bliss GVS Pharma (NSE:BLISSGVS) EPS (Basic): ₹12.13 (TTM As of Mar. 2026)


NSE:BLISSGVS Bliss GVS Pharma Ltd NSE:BLISSGVS
64 GF Score
Price ₹460.10
GF Value ₹152.39
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Bliss GVS Pharma EPS (Basic)?

Bliss GVS Pharma NSE:BLISSGVS -2.12% 64 EPS (Basic) is ₹12.13 as of Mar. 2026. GuruFocus rates NSE:BLISSGVS with a GF Score™ of 64/100 and a GF Value™ of ₹152.39 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Bliss GVS Pharma's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was ₹3.27. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹12.13.

Bliss GVS Pharma's EPS (Diluted) for the three months ended in Mar. 2026 was ₹3.27. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹11.99.

Bliss GVS Pharma's EPS without NRI for the three months ended in Mar. 2026 was ₹3.27. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was 12.13.

During the past 12 months, Bliss GVS Pharma's average EPS without NRIGrowth Rate was 53.00% per year. During the past 3 years, the average EPS without NRI Growth Rate was 21.20% per year. During the past 5 years, the average EPS without NRI Growth Rate was 10.80% per year. During the past 10 years, the average EPS without NRI Growth Rate was 6.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Bliss GVS Pharma's highest 3-Year average EPS without NRI Growth Rate was 64.50% per year. The lowest was -16.30% per year. And the median was 9.80% per year.

Bliss GVS Pharma  (NSE:BLISSGVS) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Bliss GVS Pharma EPS (Basic) Related Terms

Bliss GVS Pharma EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Bliss GVS Pharma's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bliss GVS Pharma EPS (Basic) Chart

Bliss GVS Pharma Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.46 6.83 7.23 8.02 12.23

Bliss GVS Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.47 4.08 2.58 2.20 3.27
NSE:BLISSGVS
64GF Score
Bliss GVS Pharma Ltd NSE:BLISSGVS
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bliss GVS Pharma EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Bliss GVS Pharma's Basic EPS for the fiscal year that ended in Mar. 2026 is calculated as

Basic EPS (A: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(1291.292-0)/105.584
=12.23

Bliss GVS Pharma's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(355.751-0)/108.792
=3.27

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹12.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of ₹12.13 mean?
Bliss GVS Pharma (NSE:BLISSGVS) has a EPS (Basic) of ₹12.13 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Bliss GVS Pharma and its competitors.
Is Bliss GVS Pharma's EPS (Basic) too high?
Bliss GVS Pharma's current EPS (Basic) is ₹12.13. Overall, Bliss GVS Pharma has a GF Score™ of 64/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bliss GVS Pharma's EPS (Basic) compare to ZTS?
Bliss GVS Pharma's EPS (Basic) of ₹12.13 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Drug Manufacturers company?
A good EPS (Basic) depends on the Drug Manufacturers industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Bliss GVS Pharma and its competitors. Bliss GVS Pharma's current EPS (Basic) is ₹12.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bliss GVS Pharma stock overvalued right now?
Based on GuruFocus' analysis, Bliss GVS Pharma (NSE:BLISSGVS) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹152.39, compared to a current price of ₹460.10 — trading 201.9% above its estimated fair value. The current EPS (Basic) is ₹12.13. Bliss GVS Pharma's overall GF Score™ is 64/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Bliss GVS Pharma (NSE:BLISSGVS), the current EPS (Basic) is ₹12.13 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bliss GVS Pharma (NSE:BLISSGVS) Overvalued in 2026?

Based on GuruFocus' analysis, Bliss GVS Pharma stock appears to be overvalued. The current stock price of ₹460.10 is trading 201.9% above its estimated GF Value™ of ₹152.39. GuruFocus considers Bliss GVS Pharma to be Significantly Overvalued.

Key valuation signals for NSE:BLISSGVS:

  • EPS (Basic): ₹12.13
  • GF Value™: ₹152.39 vs. price of ₹460.10 (201.9% above fair value)
  • GF Score™: 64/100 with 7 warning signs

No single metric tells the full story. See the NSE:BLISSGVS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bliss GVS Pharma Business Description

Other Exchanges 506197:India
Address Saki Vihar Road, 102, Hyde Park, Andheri (East), Mumbai, MH, IND, 400072
Bliss GVS Pharma Ltd is an India-based company engaged in the manufacturing, marketing, trading, and export of pharmaceutical products. Some of its brands include Lonart, P-Alaxin, Funbact, and Lofnac, and others. It offers pharma products including tablets, suspensions, suppositories, and injections. The majority of its revenue is derived from Exports.
64GF Score

Get the complete analysis for NSE:BLISSGVS

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹460.10
Price
₹152.39
GF Value